BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17303626)

  • 1. Reduction of site-specific CYP3A-mediated metabolism for dual angiotensin and endothelin receptor antagonists in various in vitro systems and in cynomolgus monkeys.
    Zhang H; Zhang D; Li W; Yao M; D'Arienzo C; Li YX; Ewing WR; Gu Z; Zhu Y; Murugesan N; Shyu WC; Humphreys WG
    Drug Metab Dispos; 2007 May; 35(5):795-805. PubMed ID: 17303626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys.
    Uehara S; Murayama N; Nakanishi Y; Zeldin DC; Yamazaki H; Uno Y
    J Pharmacol Exp Ther; 2011 Nov; 339(2):654-61. PubMed ID: 21849623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737): identification of an unusual N-acetylglucosamine conjugate in the cynomolgus monkey.
    Johnson BM; Kamath AV; Leet JE; Liu X; Bhide RS; Tejwani RW; Zhang Y; Qian L; Wei DD; Lombardo LJ; Shu YZ
    Drug Metab Dispos; 2008 Dec; 36(12):2475-83. PubMed ID: 18787055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
    Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
    Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
    J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
    Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
    J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes.
    Yoda N; Emoto C; Date S; Kondo S; Miyake M; Nakazato S; Umehara K; Kashiyama E
    Xenobiotica; 2012 Aug; 42(8):719-30. PubMed ID: 22324396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
    Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
    Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.
    Prueksaritanont T; Kuo Y; Tang C; Li C; Qiu Y; Lu B; Strong-Basalyga K; Richards K; Carr B; Lin JH
    Drug Metab Dispos; 2006 Sep; 34(9):1546-55. PubMed ID: 16782766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro characterization of 4'-(p-toluenesulfonylamide)-4-hydroxychalcone using human liver microsomes and recombinant cytochrome P450s.
    Lee B; Wu Z; Lee T; Tan XF; Park KH; Liu KH
    Xenobiotica; 2016; 46(4):350-6. PubMed ID: 26330107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction.
    Wong SG; Fan PW; Subramanian R; Tonn GR; Henne KR; Johnson MG; Tadano Lohr M; Wong BK
    Drug Metab Dispos; 2010 May; 38(5):841-50. PubMed ID: 20100816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
    Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
    Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone.
    Mutlib AE; Klein JT
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1285-93. PubMed ID: 9732390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
    Thummel KE; O'Shea D; Paine MF; Shen DD; Kunze KL; Perkins JD; Wilkinson GR
    Clin Pharmacol Ther; 1996 May; 59(5):491-502. PubMed ID: 8646820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles.
    Emoto C; Yoda N; Uno Y; Iwasaki K; Umehara K; Kashiyama E; Yamazaki H
    Curr Drug Metab; 2013 Feb; 14(2):239-52. PubMed ID: 22963393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
    Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
    Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism and clinical pharmacokinetics of 2-methyl-n-(2'-(pyrrolidinyl-1-ylsulfonyl)-n-[1,1'-biphenyl]-4-yl)propran-1-amine: insights into monoamine oxidase- and CYP-mediated disposition by integration of in vitro ADME tools.
    Sawant Basak A; Byon W; Tseng-Lovering E; Funk C; Wood L; Lin C; Delnomdedieu M; Verhoest P; Parikh V; Cox LM; Miller E; Gao H; Obach RS
    Xenobiotica; 2014 May; 44(5):438-54. PubMed ID: 24304147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A.
    Voorman RL; Maio SM; Hauer MJ; Sanders PE; Payne NA; Ackland MJ
    Drug Metab Dispos; 1998 Jul; 26(7):631-9. PubMed ID: 9660845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
    Yamazaki H; Shimada T
    Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
    Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
    Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.